Details of the Drug Combinations

General Information of This Drug (ID: DMQI43G)

Drug Name

BMS 650032 DMQI43G

Synonyms

Asunaprevir; 630420-16-5; BMS-650032; UNII-S9X0KRJ00S; BMS 650032; S9X0KRJ00S; Asunaprevir (BMS-650032); N-(Tert-Butoxycarbonyl)-3-Methyl-L-Valyl-(4r)-4-[(7-Chloro-4-Methoxyisoquinolin-1-Yl)oxy]-N-{(1r,2s)-1-[(Cyclopropylsulfonyl)carbamoyl]-2-Ethenylcyclopropyl}-L-Prolinamide; Asunaprevir [USAN:INN]; Sunvepra (TN); tert-butyl N-[(1S)-1-[(2S,4R)-4-[(7-chloro-4-methoxy-1-isoquinolyl)oxy]-2-[[(1R,2S)-1-(cyclopropylsulfonylcarbamoyl)-2-vinyl-cyclopropyl]carbamoyl]pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]carbamate; 2R9

Indication

Disease Entry	ICD 11	Status	REF
Hepatitis C virus infection	1E51.1	Phase 2	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

2 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
BMS 650032 + Daclatasvir	DC4I062	Daclatasvir	Hepatitis C Virus	[2]
BMS 650032 + Daclatasvir	DCENZT8	Daclatasvir	Hepatitis C Virus Infection	[3]
------------------------------------------------------------------------------------

References

1	2011 Pipeline of Bristol-Myers Squibb.
2	ClinicalTrials.gov (NCT01581203) Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)
3	ClinicalTrials.gov (NCT01428063) Study of pegInterferon Alfa-2a, Ribavirin, and Daclatasvir (BMS-790052) With or Without BMS-650032 for Participants in Some Hepatitis C Virus Trials